Methods: We utilized the Truven MarketScan Database containing individual-level claims data from medical payers and Medicare supplemental plans for 80 million lives in the U.S. from 1/2010 through 7/2014. Within this dataset, an HAE population (n=1063) and 2 control populations: an angioedema population (n=138,851) and the general population (n=79,971,098) exclusive of HAE patients were defined using a combination of ICD-9 and prescription drug codes. Claims for comorbid diseases were identified and compared across the populations with calculated odds ratios and 95% confidence intervals (CI).
Results: In the HAE population, SLE was observed 2.3 times more often (OR 2.30, 95%CI: 1.47-3.59) than the angioedema control population. Neuropathic pain was observed 1.45 times (OR 1.45, 95%CI: 1.01-2.09) and systemic mastocytosis 4.79 times (OR 4.79, 95%CI: 1.51-15.18) more often than the angioedema control population.
Conclusions: In an analysis of a large longitudinal claims database, comorbid diseases of SLE, neuropathic pain and systemic mastocytosis had a greater representation in HAE patients than other angioedema patients, suggesting that activity of the KKS may be contributing to the manifestations of these diseases.